Humam Kadara, Ph.D.

Peer-Reviewed Articles

1. Liu, Y, Sinjab, A, Min, J, Han, G, Paradiso, F, Zhang, Y, Wang, R, Pei, G, Dai, Y, Liu, Y, Cho, KS, Dai, E, Basi, A, Burks, JK, Rajapakshe, K, Chu, Y, Jiang, J, Zhang, D, Yan, X, Guerrero, PA, Serrano, A, Li, M, Hwang, TH, Futreal, A, Ajani, JA, Solis-Soto, L, Jazaeri, AA, Kadara, HN, Maitra, A, Wang, L. Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer cell 43(5):905-924.e6, 2025. e-Pub 2025. PMID: 40154487.
2. Jiang, J, Liu, Y, Qin, JJ, Chen, J, Wu, J, Pizzi, M, Segura Lazcano, R, Yamashita, K, Xu, Z, Pei, G, Cho, KS, Chu, Y, Sinjab, A, Peng, F, Yan, X, Han, G, Wang, R, Dai, E, Dai, Y, Czerniak, BA, Futreal, A, Maitra, A, Lazar, A, Kadara, HN, Jazaeri, AA, Cheng, X, Ajani, JA, Gao, J, Hu, J, Wang, L. METI. Nature communications 15(1), 2024. e-Pub 2024. PMID: 39181865.
3. Rahal, Z, Liu, Y, Peng, F, Yang, S, Jamal, M, Sharma, M, Moreno, H, Damania, A, Wong, M, Ross, MC, Sinjab, A, Zhou, T, Chen, M, Reischle, IT, Feng, J, Chukwuocha, C, Tang, EL, Abaya, C, Lim, JK, Leung, CH, Lin, HY, Deboever, N, Lee, JJ, Sepesi, B, Gibbons, DL, Wargo, J, Fujimoto, J, Wang, L, Petrosino, JF, Ajami, NJ, Jenq, RR, Moghaddam, SM, Cascone, T, Hoffman, KL, Kadara, HN. Inflammation Mediated by Gut Microbiome Alterations Promotes Lung Cancer Development and an Immunosuppressed Tumor Microenvironment. Cancer Immunology Research 12(12):1736-1752, 2024. e-Pub 2024. PMID: 39269772.
4. Zhou, N, Leung, CH, William Jr, WN, Weissferdt, A, Pataer, A, Godoy, M, Carter, B, Fossella, FV, Tsao, A, Blumenschein, GR, Le, X, Zhang, J, Skoulidis, F, Kurie, JM, Altan, M, Lu, C, Glisson, BS, Byers, LA, Elamin, YY, Mehran, RJ, Rice, DC, Walsh, GL, Hofstetter, WL, Roth, JA, Tran, HT, Wu, J, Solis Soto, LM, Kadara, HN, Swisher, SG, Vaporciyan, AA, Gibbons, DL, Lin, HY, Jack Lee, J, Heymach, JV, Vailati Negrao, M, Sepesi, B, Cascone, T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. Journal for immunotherapy of cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
5. Moghaddam, SM, Savai, R, Keith, RL, Bauer, AK, Beane, J, Dubinett, SM, Houghton, AG, Jenkins, BJ, Kadara, HN, Kammer, MN, Kim, CF, Massion, PP, Ostrin, EJ, Powell, CA, Priolo, C, Rivera, MP, Salehi-Rad, R, Sears, CR, Sengupta, S, Stabile, LP, Szabo, E, Tennis, MA. Premalignant Progression in the Lung. American journal of respiratory and critical care medicine 210(5):548-571, 2024. e-Pub 2024. PMID: 39115548.
6. Seth, S, Chen, R, Liu, Y, Fujimoto, J, Hong, L, Reuben, A, Varghese, S, Behrens, MC, McDowell, TL, Solis Soto, LM, Haymaker, CL, Weissferdt, A, Kalhor, N, Wu, J, Le, X, Vokes, N, Cheng, C, Heymach, JV, Gibbons, DL, Futreal, A, Wistuba, II, Kadara, HN, Zhang, J, Moran, C, Zhang, J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innovation 3(3), 2024. e-Pub 2024. PMID: 38947760.
7. Seth S, Chen R, Liu Y, Fujimoto J, Hong L, Reuben A, Varghese S, Behrens C, McDowell T, Soto LS, Haymaker C, Weissferdt A, Kalhor N, Wu J, Le X, Vokes NI, Cheng C, Heymach JV, Gibbons DL, Futreal PA, Wistuba II, Kadara H, Zhang J, Moran C, Zhang J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innov 3(3):e112, 2024. e-Pub 2024. PMID: 38947760.
8. Rahal Z, Scheet P, Kadara H. Somatic Mutations in Normal Tissues: Calm before the Storm. Cancer Discov 14(4):605-609, 2024. e-Pub 2024. PMID: 38571416.
9. Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H. Author Correction: An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature 628(8006):E1, 2024. e-Pub 2024. PMID: 38499683.
10. Han G, Sinjab A, Rahal Z, Lynch AM, Treekitkarnmongkol W, Liu Y, Serrano AG, Feng J, Liang K, Khan K, Lu W, Hernandez SD, Liu Y, Cao X, Dai E, Pei G, Hu J, Abaya C, Gomez-Bolanos LI, Peng F, Chen M, Parra ER, Cascone T, Sepesi B, Moghaddam SJ, Scheet P, Negrao MV, Heymach JV, Li M, Dubinett SM, Stevenson CS, Spira AE, Fujimoto J, Solis LM, Wistuba II, Chen J, Wang L, Kadara H. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature 627(8004):656-663, 2024. e-Pub 2024. PMID: 38418883.
11. Dacic S, Cao X, Bota-Rabassedas N, Sanchez-Espiridion B, Berezowska S, Han Y, Chung JH, Beasley MB, Dongmei L, Hwang D, Mino-Kenudson M, Minami Y, Papotti M, Rekhtman N, Roden AC, Thunnissen E, Tsao MS, Yatabe Y, Yoshida A, Wang L, Hartman DJ, Jerome JA, Kadara H, Chou TY, Wistuba II, Committee IP. Genomic Staging of Multifocal Lung Squamous Cell Carcinomas Is Independent of the Comprehensive Morphologic Assessment. J Thorac Oncol 19(2):273-284, 2024. e-Pub 2024. PMID: 37717856.
12. Rahal Z, Kadara H. Beyond bacteria: How the intratumor mycobiome modulates lung adenocarcinoma progression. Cancer Cell 41(11):1846-1848, 2023. e-Pub 2023. PMID: 37774700.
13. Yanagawa J, Tran LM, Salehi-Rad R, Lim RJ, Dumitras C, Fung E, Wallace WD, Prosper AE, Fishbein G, Shea C, Hong R, Kahangi B, Deng JJ, Gower AC, Liu B, Campbell JD, Mazzilli SA, Beane JE, Kadara H, Lenburg ME, Spira AE, Aberle DR, Krysan K, Dubinett SM. Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma. Cancer Res 83(19):3305-3319, 2023. e-Pub 2023. PMID: 37477508.
14. Rahal Z, Sinjab A, Wistuba II, Kadara H. Corrigendum to "Game of clones: Battles in the field of carcinogenesis" [Pharmacology & Therapeutics, volume 237, Pages 108-251]. Pharmacol Ther 247:108446, 2023. e-Pub 2023. PMID: 37210813.
15. Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med 29(6):1550-1562, 2023. e-Pub 2023. PMID: 37248301.
16. Hu J, Coleman K, Zhang D, Lee EB, Kadara H, Wang L, Li M. Deciphering tumor ecosystems at super resolution from spatial transcriptomics with TESLA. Cell Syst 14(5):404-417.e4, 2023. e-Pub 2023. PMID: 37164011.
17. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
18. Francisco-Cruz A, Rocha P, Reuben A, Krishnan SN, Das P, Chen R, Quek K, Li J, Parra ER, Solis LM, Barua S, Jiang M, Lazcano R, Chow CW, Behrens C, Gumb C, Little L, Fukuoka J, Kalhor N, Weissferdt A, Kadara H, Heymach JV, Swisher S, Sepesi B, Rao A, Moran C, Zhang J, Lee JJ, Fujimoto J, Futreal PA, Wistuba II, Peterson CB, Zhang J. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol 36(1):100028, 2023. e-Pub 2023. PMID: 36788067.
19. Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo JA, Swisher SG, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett SM, Fujimoto J, Solis Soto LM, Wistuba II, Stevenson CS, Spira A, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov 12(11):2626-2645, 2022. e-Pub 2022. PMID: 36098652.
20. Finnicum CT, Rahal Z, Hassane M, Treekitkarnmongkol W, Sinjab A, Morris R, Liu Y, Tang EL, Viet S, Petersen JL, Lorenzi PL, Tan L, Petrosino J, Hoffman KL, Fujimoto J, Moghaddam SJ, Kadara H. Pathogenesis of Tobacco-Associated Lung Adenocarcinoma Is Closely Coupled with Changes in the Gut and Lung Microbiomes. Int J Mol Sci 23(18), 2022. e-Pub 2022. PMID: 36142843.
21. Irajizad E, Fahrmann JF, Long JP, Vykoukal J, Kobayashi M, Capello M, Yu CY, Cai Y, Hsiao FC, Patel N, Park S, Peng Q, Dennison JB, Kato T, Tai MC, Taguchi A, Kadara H, Wistuba II, Katayama H, Do KA, Hanash SM, Ostrin EJ. A Comprehensive Search of Non-Canonical Proteins in Non-Small Cell Lung Cancer and Their Impact on the Immune Response. Int J Mol Sci 23(16), 2022. e-Pub 2022. PMID: 36012199.
22. Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun 13(1):4327, 2022. e-Pub 2022. PMID: 35882862.
23. Hassane M, Rahal Z, Karaoghlanian N, Zhang J, Sinjab A, Wong JW, Lu W, Scheet P, Lee JJ, Raso MG, Solis LM, Fujimoto J, Chami H, Shihadeh AL, Kadara H. Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung. Cancer Prev Res (Phila) 15(7):423-434, 2022. e-Pub 2022. PMID: 35468191.
24. Yuan B, Clowers MJ, Velasco WV, Peng S, Peng Q, Shi Y, Ramos-Castaneda M, Zarghooni M, Yang S, Babcock RL, Chang SH, Heymach JV, Zhang J, Ostrin EJ, Watowich SS, Kadara H, Moghaddam SJ. Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer. JCI Insight 7(11), 2022. e-Pub 2022. PMID: 35471938.
25. Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridon B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clin Cancer Res 28(11):2461-2473, 2022. e-Pub 2022. PMID: 35394499.
26. Pantaleón García J, Kulkarni VV, Reese TC, Wali S, Wase SJ, Zhang J, Singh R, Caetano MS, Kadara H, Moghaddam SJ, Johnson FM, Wang J, Wang Y, Evans SE. OBIF: an omics-based interaction framework to reveal molecular drivers of synergy. NAR Genom Bioinform 4(2):lqac028, 2022. e-Pub 2022. PMID: 35387383.
27. Schapiro D, Yapp C, Sokolov A, Reynolds SM, Chen YA, Sudar D, Xie Y, Muhlich J, Arias-Camison R, Arena S, Taylor AJ, Nikolov M, Tyler M, Lin JR, Burlingame EA, Atlas Network HT, Chang YH, Farhi SL, Thorsson V, Venkatamohan N, Drewes JL, Pe'er D, Gutman DA, Herrmann MD, Gehlenborg N, Bankhead P, Roland JT, Herndon JM, Snyder MP, Angelo M, Nolan G, Swedlow JR, Schultz N, Merrick DT, Mazzili SA, Cerami E, Rodig SJ, Santagata S, Sorger PK. MITI minimum information guidelines for highly multiplexed tissue images. Nat Methods 19(3):262-267, 2022. e-Pub 2022. PMID: 35277708.
28. Devarakonda S, Li Y, Martins Rodrigues F, Sankararaman S, Kadara H, Goparaju C, Lanc I, Pepin K, Waqar SN, Morgensztern D, Ward J, Masood A, Fulton R, Fulton L, Gillette MA, Satpathy S, Carr SA, Wistuba I, Pass H, Wilson RK, Ding L, Govindan R. Genomic Profiling of Lung Adenocarcinoma in Never-Smokers. J Clin Oncol 39(33):3747-3758, 2021. e-Pub 2021. PMID: 34591593.
29. Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, Garcia-Campelo R, Lázaro M, Dómine M, Majem M, Rodríguez-Abreu D, Martinez-Marti A, de Castro-Carpeño J, Cobo M, López-Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Barquin M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Pre-treatment tissue TCR repertoire evenness is associated with complete pathological response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy. Clin Cancer Res 27(21):5878-5890, 2021. e-Pub 2021. PMID: 34376534.
30. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology. J Thorac Oncol 16(11):1821-1839, 2021. e-Pub 2021. PMID: 34274504.
31. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov 11(10):2506-2523, 2021. e-Pub 2021. PMID: 33972311.
32. Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
33. Kadara H, Tran LM, Liu B, Vachani A, Li S, Sinjab A, Zhou XJ, Dubinett SM, Krysan K. Early Diagnosis and Screening for Lung Cancer. Cold Spring Harb Perspect Med 11(9), 2021. e-Pub 2021. PMID: 34001525.
34. Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
35. Bazzi S, El-Darzi E, McDowell T, Modjtahedi H, Mudan S, Achkar M, Akle C, Kadara H, Bahr GM. Cytokine/Chemokine Release Patterns and Transcriptomic Profiles of LPS/IFNγ-Activated Human Macrophages Differentiated with Heat-Killed Mycobacterium obuense, M-CSF, or GM-CSF. Int J Mol Sci 22(13), 2021. e-Pub 2021. PMID: 34281268.
36. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1965-1976, 2021. e-Pub 2021. PMID: 33416944.
37. Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, Su D, Fukuoka J, Tabata K, Pham HHN, Mcgranahan N, Zhang B, Ye J, Ying L, Little L, Gumbs C, Chow CW, Estecio MR, Godoy MCB, Antonoff MB, Sepesi B, Pass HI, Behrens C, Zhang J, Vaporciyan AA, Heymach JV, Scheet P, Lee JJ, Wu J, Futreal PA, Reuben A, Kadara H, Wistuba II, Zhang J. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun 12(1):2722, 2021. e-Pub 2021. PMID: 33976164.
38. Behrens C, Rocha P, Parra ER, Feng L, Rodriguez-Canales J, Solis LM, Mino B, Zhang J, Gibbons DL, Sepesi B, Rice D, Heymach JV, Moran C, Creighton CJ, Lee JJ, Kadara H, Wistuba II. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer 22(3):e415-e424, 2021. e-Pub 2020. PMID: 32763065.
39. Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol 16(4):583-600, 2021. e-Pub 2021. PMID: 33388477.
40. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6):1-13, 2021. e-Pub 2021. PMID: 33809063.
41. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
42. Bahmad HF, Chalhoub RM, Harati H, Bou-Gharios J, Assi S, Ballout F, Monzer A, Msheik H, Araji T, Elajami MK, Ghanem P, Chamaa F, Kadara H, Abou-Antoun T, Daoud G, Fares Y, Abou-Kheir W. Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK-3β. Pharmacol Rep 73(1):211-226, 2021. e-Pub 2021. PMID: 33030673.
43. Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, Chow CW, Pham HHN, Godoy MCB, Carter BW, Behrens C, Zhang J, Antonoff MB, Sepesi B, Lu Y, Pass HI, Kadara H, Scheet P, Vaporciyan AA, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Su D, Issa JJ, Zhang J. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun 12(1):687, 2021. e-Pub 2021. PMID: 33514726.
44. Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets T, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara H, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer. J Thorac Oncol 16(1):127-139, 2021. e-Pub 2020. PMID: 33096269.
45. Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, Zhang J, Lu W, Sivakumar S, McDowell TL, Kantrowitz J, Zhou J, Lang W, Xu L, Ochieng JK, Nunomura-Nakamura S, Deng S, Behrens C, Raso MG, Fukuoka J, Reuben A, Ostrin EJ, Parra E, Solis LM, Spira AE, McAllister F, Cascone T, Wistuba II, Moghaddam SJ, Scheet PA, Fujimoto J, Kadara H. Augmented Lipocalin-2 is Associated with COPD and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med 203(1):90-101, 2021. e-Pub 2021. PMID: 32730093.
46. Sinjab A, Daouk R, Abou-Kheir W, Kadara H. Whole Transcriptome Sequencing Analysis of Cancer Stem/Progenitor Cells Obtained from Mouse Lung Adenocarcinomas. Methods Mol Biol 2279:187-198, 2021. e-Pub 2021. PMID: 33683695.
47. Fakhri G, Akel R, Khalifeh I, Chami H, Hajj Ali A, Al Assaad M, Atwi H, Kadara H, Tfayli A. Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon. SAGE Open Med 9:20503121211043709, 2021. e-Pub 2021. PMID: 34540227.
48. Sinjab A, Han G, Wang L, Kadara H. Field Carcinogenesis in Cancer Evolution: What the Cell Is Going On?. Cancer Res 80(22):4888-4891, 2020. e-Pub 2020. PMID: 33023945.
49. Deng S, Ramos-Castaneda M, Velasco WV, Clowers MJ, Gutierrez BA, Noble O, Dong Y, Zarghooni M, Alvarado L, Caetano MS, Yang S, Ostrin EJ, Behrens C, Wistuba II, Stabile LP, Kadara H, Watowich SS, Moghaddam SJ. Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer. Carcinogenesis 41(11):1529-1542, 2020. e-Pub 2020. PMID: 32603404.
50. Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother 69(8):1519-1534, 2020. e-Pub 2020. PMID: 32300858.
51. Al Matari N, Deeb G, Mshiek H, Sinjab A, Kadara H, Abou-Kheir W, Mhanna R. Anti-Tumor Effects of Biomimetic Sulfated Glycosaminoglycans on Lung Adenocarcinoma Cells in 2D and 3D In Vitro Models. Molecules 25(11), 2020. e-Pub 2020. PMID: 32503108.
52. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Maria Della Corte C, Fan Y, Kundu K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models. bioRxiv, 2020. e-Pub 2020. PMID: 32577652.
53. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
54. Daouk R, Bahmad HF, Saleh E, Monzer A, Ballout F, Kadara H, Abou-Kheir W. Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets. PLoS One 15(8):e0237442, 2020. e-Pub 2020. PMID: 32790767.
55. Makoukji J, El-Sitt S, Makhoul NJ, Soueid J, Kadara H, Boustany RM. Sex differences in gene expression with galactosylceramide treatment in Cln3?ex7/8 mice. PLoS One 15(10):e0239537, 2020. e-Pub 2020. PMID: 33006978.
56. Jakubek YA, Chang K, Sivakumar S, Yu Y, Giordano MR, Fowler J, Huff CD, Kadara H, Vilar E, Scheet P. Large-scale analysis of acquired chromosomal alterations in non-tumor samples from patients with cancer. Nat Biotechnol. e-Pub 2019. PMID: 31685958.
57. Shi B, Behrens C, Vaghani V, Riquelme EM, Rodriguez-Canales J, Kadara H, Lin H, Lee J, Liu H, Wistuba I, Simon G. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer. Cancer Med 8(14):6383-6392, 2019. e-Pub 2019. PMID: 31456359.
58. Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. Am J Respir Crit Care Med 200(6):742-750, 2019. e-Pub 2019. PMID: 30896962.
59. Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol 30(9):1521-1530, 2019. e-Pub 2019. PMID: 31282941.
60. Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun 10(1):2978, 2019. e-Pub 2019. PMID: 31278276.
61. Khoueiry P, Fakhri G, Akel R, El Assaad M, Mahfouz R, Khuri F, Chami H, Petersen J, Viet S, Davies G, Kadara H, Tfayli A. Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population. J Thorac Dis 11(6):2383-2391, 2019. e-Pub 2019. PMID: 31372275.
62. Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal PA, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine 42:296-303, 2019. e-Pub 2019. PMID: 30905849.
63. Nehme E, Rahal Z, Sinjab A, Khalil A, Chami H, Nemer G, Kadara H. Epigenetic Suppression of the T-box Subfamily 2 (TBX2) in Human Non-Small Cell Lung Cancer. Int J Mol Sci 20(5), 2019. e-Pub 2019. PMID: 30866410.
64. Daouk R, Hassane M, Bahmad HF, Sinjab A, Fujimoto J, Abou-Kheir W, Kadara H. Genome-Wide and Phenotypic Evaluation of Stem Cell Progenitors Derived From Gprc5a-Deficient Murine Lung Adenocarcinoma With Somatic Kras Mutations. Front Oncol 9:207, 2019. e-Pub 2019. PMID: 31001473.
65. Caetano MS, Hassane M, Van HT, Bugarin E, Cumpian AM, McDowell CL, Cavazos CG, Zhang H, Deng S, Diao L, Wang J, Evans SE, Behrens C, Wistuba II, Fuqua SAW, Lin H, Stabile LP, Watowich SS, Kadara H, Moghaddam SJ. Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nat Commun 9(1):4589, 2018. e-Pub 2018. PMID: 30389925.
66. Bauer AK, Umer M, Richardson VL, Cumpian AM, Harder AQ, Khosravi N, Azzegagh Z, Hara NM, Ehre C, Mohebnasab M, Caetano MS, Merrick DT, van Bokhoven A, Wistuba II, Kadara H, Dickey BF, Velmurugan K, Mann PR, Lu X, Barón AE, Evans CM, Moghaddam SJ. Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. JCI Insight 3(15). e-Pub 2018. PMID: 30089720.
67. Khosravi N, Caetano MS, Cumpian AM, Unver N, De la Garza Ramos C, Noble O, Daliri S, Hernandez BJ, Gutierrez BA, Evans SE, Hanash S, Alekseev AM, Yang Y, Chang SH, Nurieva R, Kadara H, Chen J, Ostrin EJ, Moghaddam SJ. IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties. Cancer Immunol Res 6(7):788-797, 2018. e-Pub 2018. PMID: 29764837.
68. Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol 29(4):1072, 2018. e-Pub 2018. PMID: 29688333.
69. Kantrowitz J, Sinjab A, Xu L, McDowell TL, Sivakumar S, Lang W, Nunomura-Nakamura S, Fukuoka J, Nemer G, Darwiche N, Chami H, Tfayli A, Wistuba II, Scheet P, Fujimoto J, Spira AE, Kadara H. Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma. Cancer Prev Res (Phila) 11(4):237-248, 2018. e-Pub 2018. PMID: 29382653.
70. Bergqvist C, Kadara H, Hamie L, Nemer G, Safi R, Karouni M, Marrouche N, Abbas O, Hasbani DJ, Kibbi AG, Nassar D, Shimomura Y, Kurban M. SLURP-1 is mutated in Mal de Meleda, a potential molecular signature for melanoma and a putative squamous lineage tumor suppressor gene. Int J Dermatol 57(2):162-170, 2018. e-Pub 2018. PMID: 29231248.
71. Deshpande A, Lang W, McDowell T, Sivakumar S, Zhang J, Wang J, San Lucas FA, Fowler J, Kadara H, Scheet P. Strategies for identification of somatic variants using the Ion Torrent deep targeted sequencing platform. BMC Bioinformatics 19(1):5, 2018. e-Pub 2018. PMID: 29301485.
72. Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR, Head, Supplement Consortium NCSPOREHIV. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124(1):84-94, 2018. e-Pub 2018. PMID: 29053175.
73. Khalil A, Dekmak B, Boulos F, Kantrowitz J, Spira A, Fujimoto J, Kadara H, El-Hachem N, Nemer G. Transcriptomic Alterations in Lung Adenocarcinoma Unveil New Mechanisms Targeted by the TBX2 Subfamily of Tumor Suppressor Genes. Front Oncol 8:482, 2018. e-Pub 2018. PMID: 30425966.
74. Abdel-Samad R, Aouad P, Gali-Muhtasib H, Sweidan Z, Hmadi R, Kadara H, D'Andrea EL, Fucci A, Pisano C, Darwiche N. Mechanism of action of the atypical retinoid ST1926 in colorectal cancer: DNA damage and DNA polymerase α. Am J Cancer Res 8(1):39-55, 2018. e-Pub 2018. PMID: 29416919.
75. Nassar FJ, Talhouk R, Zgheib NK, Tfayli A, El Sabban M, El Saghir NS, Boulos F, Jabbour MN, Chalala C, Boustany RM, Kadara H, Zhang Z, Zheng Y, Joyce B, Hou L, Bazarbachi A, Calin G, Nasr R. microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysis. Sci Rep 7(1):16829, 2017. e-Pub 2017. PMID: 29203780.
76. Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res 77(22):6119-6130, 2017. e-Pub 2017. PMID: 28951454.
77. Kadara H, Nemer G, Safi R, Rebeiz N, Daou L, Delbani D, Btadini W, Abbas O, Tofaili M, Bitar F, Kibbi AG, Shimomura Y, Kurban M. Erythropoietic protoporphyria a clinical and molecular study from Lebanon: Ferrochelatase a potential tumor suppressor gene in colon cancer. Clin Genet 92(5):495-502, 2017. e-Pub 2017. PMID: 28075030.
78. Fujimoto J, Nunomura-Nakamura S, Liu Y, Lang W, McDowell T, Jakubek Y, Ezzeddine D, Kapere Ochieng J, Petersen J, Davies G, Fukuoka J, Wistuba II, Ehli E, Fowler J, Scheet P, Kadara H. Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a. Int J Cancer 141(8):1589-1599, 2017. e-Pub 2017. PMID: 28653505.
79. Khalil AA, Sivakumar S, Lucas FAS, McDowell T, Lang W, Tabata K, Fujimoto J, Yatabe Y, Spira A, Scheet P, Nemer G, Kadara H. TBX2 subfamily suppression in lung cancer pathogenesis: a high-potential marker for early detection. Oncotarget 8(40):68230-68241, 2017. e-Pub 2017. PMID: 28978111.
80. Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. Clin Cancer Res 23(18):5489-5501, 2017. e-Pub 2017. PMID: 28559461.
81. Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol 28(1):83-89, 2017. e-Pub 2017. PMID: 28177435.
82. Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol 28(1):75-82, 2017. e-Pub 2017. PMID: 27687306.
83. Bazzi S, El-Darzi E, McDowell T, Modjtahedi H, Mudan S, Achkar M, Akle C, Kadara H, Bahr GM. Defining Genome-Wide Expression and Phenotypic Contextual Cues in Macrophages Generated by Granulocyte/Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Heat-Killed Mycobacteria. Front Immunol 8:1253, 2017. e-Pub 2017. PMID: 29046677.
84. Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res 22(24):6278-6289, 2016. e-Pub 2016. PMID: 27252415.
85. Jakubek Y, Lang W, Vattathil S, Garcia M, Xu L, Huang L, Yoo SY, Shen L, Lu W, Chow CW, Weber Z, Davies G, Huang J, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran R, El-Zein R, Swisher SG, Wang J, Fowler J, Spira AE, Ehli EA, Wistuba II, Scheet P, Kadara H. Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. Cancer Res 76(13):3676-83, 2016. e-Pub 2016. PMID: 27216194.
86. Caetano MS, Zhang H, Cumpian AM, Gong L, Unver N, Ostrin EJ, Daliri S, Chang SH, Ochoa CE, Hanash S, Behrens C, Wistuba II, Sternberg C, Kadara H, Ferreira CG, Watowich SS, Moghaddam SJ. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer. Cancer Res 76(11):3189-99, 2016. e-Pub 2016. PMID: 27197187.
87. Koneru B, Shi Y, Munaweera I, Wight-Carter M, Kadara H, Yuan H, Di Pasqua AJ, Balkus KJ. Radiotherapeutic bandage for the treatment of squamous cell carcinoma of the skin. Nucl Med Biol 43(6):333-8, 2016. e-Pub 2016. PMID: 27260774.
88. Peng S, Sen B, Mazumdar T, Byers LA, Diao L, Wang J, Tong P, Giri U, Heymach JV, Kadara HN, Johnson FM. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget 7(1):565-79, 2016. e-Pub 2016. PMID: 26623721.
89. Maki Y, Fujimoto J, Lang W, Xu L, Behrens C, Wistuba II, Kadara H. LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells. Sci Rep 5:13846, 2015. e-Pub 2015. PMID: 26343532.
90. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-77, 2015. e-Pub 2015. PMID: 26069186.
91. Gold KA, Kim ES, Liu DD, Yuan P, Behrens C, Solis LM, Kadara H, Rice DC, Wistuba II, Swisher SG, Hofstetter WL, Lee JJ, Hong WK. Prediction of survival in resected non-small cell lung cancer using a protein-expression based risk model: Implications for personalized chemoprevention and therapy. Clin Cancer Res 20(7):1946-54, 2014. e-Pub 2014. PMID: 24366692.
92. Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, Garcia MM, Chow CW, Chu Z, Mendoza G, Shen L, Kalhor N, Hong WK, Moran C, Wang J, Spira A, Coombes KR, Wistuba II. Transcriptomic Architecture of the Adjacent Airway Field Cancerization in Non-Small Cell Lung Cancer. J Natl Cancer Inst 106(3):dju004, 2014. e-Pub 2014. PMID: 24563515.
93. Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, Swisher SG, Simon GR, Stewart DJ, Lee JJ, Wistuba II. EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non-Small Cell Lung Carcinoma. Clin Cancer Res 19(23):6556-65, 2013. e-Pub 2013. PMID: 24097870.
94. Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, Mendoza G, Momin AA, James BP, Solis L, Behrens C, Lee JJ, Wistuba II, Kadara H. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res 19(13):3383-95, 2013. e-Pub 2013. PMID: 23659968.
95. Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II. Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila) 6(1):8-17, 2013. e-Pub 2013. PMID: 23087048.
96. Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R, Wistuba II. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Thorac Oncol 7(12):1747-54, 2012. e-Pub 2012. PMID: 23154545.
97. Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 118(11):2889-99, 2012. e-Pub 2012. PMID: 22020674.
98. Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol 7(5):833-40, 2012. e-Pub 2012. PMID: 22729036.
99. Kadara H, Wistuba II. Field cancerization in non-small cell lung cancer: implications in disease pathogenesis. Proc Am Thorac Soc 9(2):38-42, 2012. e-Pub 2012. PMID: 22550239.
100. Kadara H, Kabbout M, Wistuba II. Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 17(1):50-65, 2012. e-Pub 2012. PMID: 22040022.
101. Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: Implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 17(8):2434-43, 2011. e-Pub 2011. PMID: 21257719.
102. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121(4):1313-28, 2011. e-Pub 2011. PMID: 21436589.
103. Kadara H, Behrens C, Yuan P, Solis L, Liu D, Gu X, Minna JD, Lee JJ, Kim E, Hong WK, Wistuba II, Lotan R. A five-gene and corresponding-protein signature for stage-I lung adenocarcinoma prognosis. Clin Cancer Res 17(6):1490-501, 2011. e-Pub 2011. PMID: 21163870.
104. Chen Y, Deng J, Fujimoto J, Kadara H, Men T, Lotan D, Lotan R. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor. Cancer Res 70(21):8917-26, 2010. e-Pub 2010. PMID: 20959490.
105. Fujimoto J, Kadara H, Men T, van Pelt C, Lotan D, Lotan R. Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5a-knockout mice. PLoS One 5(7):e11847, 2010. e-Pub 2010. PMID: 20686609.
106. Kadara H, Fujimoto J, Men T, Ye X, Lotan D, Lee JS, Lotan R. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia 12(6):499-505, 2010. e-Pub 2010. PMID: 20563252.
107. Deng J, Fujimoto J, Ye XF, Men TY, Van Pelt CS, Chen YL, Lin XF, Kadara H, Tao Q, Lotan D, Lotan R. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis. Cancer Prev Res (Phila) 3(4):424-37, 2010. e-Pub 2010. PMID: 20354164.
108. Chakravarti N, Kadara H, Yoon DJ, Shay JW, Myers JN, Lotan D, Sonenberg N, Lotan R. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prev Res (Phila) 3(3):331-8, 2010. e-Pub 2010. PMID: 20145189.
109. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 5(2):e9112, 2010. e-Pub 2010. PMID: 20161759.
110. Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba II. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions. Clin Cancer Res 16(1):34-44, 2010. e-Pub 2010. PMID: 20028769.
111. Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) 2(8):702-11, 2009. e-Pub 2009. PMID: 19638491.
112. Tahara E, Kadara H, Lacroix L, Lotan D, Lotan R. Activation of protein kinase C by phorbol 12-myristate 13-acetate suppresses the growth of lung cancer cells through KLF6 induction. Cancer Biol Ther 8(9):801-7, 2009. e-Pub 2009. PMID: 19333010.
113. Kadara H, Tahara E, Kim HJ, Lotan D, Myers J, Lotan R. Involvement of Rac in fenretinide-induced apoptosis. Cancer Res 68(11):4416-23, 2008. e-Pub 2008. PMID: 18519704.
114. Pathak AK, Bhutani M, Nair AS, Ahn KS, Chakraborty A, Kadara H, Guha S, Sethi G, Aggarwal BB. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res 5(9):943-55, 2007. e-Pub 2007. PMID: 17855663.
115. Kadara H, Lacroix L, Lotan D, Lotan R. Induction of endoplasmic reticulum stress by the pro-apoptotic retinoid N-(4-hydroxyphenyl)retinamide via a reactive oxygen species-dependent mechanism in human head and neck cancer cells. Cancer Biol Ther 6(5):705-11, 2007. e-Pub 2007. PMID: 17404501.
116. Schroeder CP, Kadara H, Lotan D, Woo JK, Lee HY, Hong WK, Lotan R. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res 66(19):9762-70, 2006. e-Pub 2006. PMID: 17018636.
117. Kadara H, Schroeder CP, Lotan D, Pisano C, Lotan R. Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of its role in apoptosis. Cancer Biol Ther 5(5):518-22, 2006. e-Pub 2006. PMID: 16582595.
118. Darwiche N, Hatoum A, Dbaibo G, Kadara H, Nasr R, Abou-Lteif G, Bazzi R, Hermine O, de Thé H, Bazarbachi A. N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells. Leukemia 18(3):607-15, 2004. e-Pub 2004. PMID: 14712289.

Invited Articles

1. Kadara H, Kabbout M, Wistuba II. Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 17(1):50-65, 2012. e-Pub 2012.
2. Kadara H, Wistuba II. Field cancerization in NSCLC: implications in disease pathogenesis. Proceedings of the American Thoracic Society 9(2):38-42, 2012. e-Pub 2012.
3. Kadara H. Reuben Lotan, Ph.D. (1946-2011): in memoriam. Cancer Biol Ther 12(12):1015-7, 2011. e-Pub 2011. PMID: 22236874.

Review Articles

1. Rahal, Z, Rahal, Z, El Darzi, R, El Darzi, R, Moghaddam, SM, Moghaddam, SM, Cascone, T, Cascone, T, Kadara, HN, Kadara, HN. Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nature Reviews Clinical Oncology 22(7):463-482, 2025. e-Pub 2025. PMID: 40379986.
2. Mazzilli, SA, Mazzilli, SA, Rahal, Z, Rahal, Z, Rouhani, MJ, Rouhani, MJ, Janes, SM, Janes, SM, Kadara, HN, Kadara, HN, Dubinett, SM, Dubinett, SM, Spira, A, Spira, A. Translating premalignant biology to accelerate non-small-cell lung cancer interception. Nature Reviews Cancer 25(5):379-392, 2025. e-Pub 2025. PMID: 39994467.
3. Rahal Z, Sinjab A, Wistuba II, Kadara H. Game of clones: Battles in the field of carcinogenesis. Pharmacol Ther 237:108251, 2022. e-Pub 2022. PMID: 35850404.
4. Sinjab A, Rahal Z, Kadara H. Cell-by-Cell: Unlocking Lung Cancer Pathogenesis. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884485.
5. Habli Z, AlChamaa W, Saab R, Kadara H, Khraiche ML. Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32708837.
6. Rozenblatt-Rosen O, Regev A, Oberdoerffer P, Nawy T, Hupalowska A, Rood JE, Ashenberg O, Cerami E, Coffey RJ, Demir E, Ding L, Esplin ED, Ford JM, Goecks J, Ghosh S, Gray JW, Guinney J, Hanlon SE, Hughes SK, Hwang ES, Iacobuzio-Donahue CA, Jané-Valbuena J, Johnson BE, Lau KS, Lively T, Mazzilli SA, Pe'er D, Santagata S, Shalek AK, Schapiro D, Snyder MP, Sorger PK, Spira AE, Srivastava S, Tan K, West RB, Williams EH, Atlas Network HT. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell 181(2):236-249, 2020. e-Pub 2020. PMID: 32302568.
7. Saab S, Zalzale H, Rahal Z, Khalifeh Y, Sinjab A, Kadara H. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Front Immunol 11:159, 2020. e-Pub 2020. PMID: 32117295.
8. Rahal Z, Abdulhai F, Kadara H, Saab R. Genomics of adult and pediatric solid tumors. Am J Cancer Res 8(8):1356-1386, 2018. e-Pub 2018. PMID: 30210910.
9. Rahal Z, El Nemr S, Sinjab A, Chami H, Tfayli A, Kadara H. Smoking and Lung Cancer: A Geo-Regional Perspective. Front Oncol 7:194, 2017. e-Pub 2017. PMID: 28920053.
10. Kadara H, Scheet P, Wistuba II, Spira AE. Early Events in the Molecular Pathogenesis of Lung Cancer. Cancer Prev Res (Phila) 9(7):518-27, 2016. e-Pub 2016. PMID: 27006378.

Other Articles

1. Bartolacci, C, Andreani, C, Vale, G, Berto, S, Melegari, M, Crouch, AC, Baluya, D, Kemble, G, Hodges, K, Starrett, J, Politi, K, Starnes, SL, Lorenzini, D, Raso, G, Solis Soto, LM, Behrens, MC, Kadara, HN, Gao, B, Wistuba, II, Minna, JD, McDonald, J, Scaglioni, PP Author Correction. Nature communications 13(1), 2022. PMID: 35941179.
2. Bartolacci, C, Andreani, C, Vale, G, Berto, S, Melegari, M, Crouch, AC, Baluya, D, Kemble, G, Hodges, K, Starrett, J, Politi, K, Starnes, SL, Lorenzini, D, Raso, G, Solis Soto, LM, Behrens, MC, Kadara, HN, Gao, B, Wistuba, II, Minna, JD, McDonald, J, Scaglioni, PP Author Correction. Nature communications 13(1), 2022. PMID: 35941179.
3. Hu, X, Fujimoto, J, Ying, L, Fukuoka, J, Ashizawa, K, Sun, W, Reuben, A, Chow, CW, Mcgranahan, N, Chen, R, Hu, J, Godoy, M, Tabata, K, Kuroda, K, Shi, L, Li, J, Behrens, MC, Parra Cuentas, ER, Little, L, Gumbs, C, Mao, X, Song, X, Tippen, S, Thornton, R, Kadara, HN, Scheet, PA, Roarty, EB, Ostrin, EJ, Wang, X, Carter, B, Antonoff, MB, Zhang, J, Vaporciyan, AA, Pass, HI, Swisher, SG, Heymach, JV, Lee, JJ, Wistuba, II, Hong, WK, Futreal, A, Su, D, Zhang, J Author Correction. Nature communications 12(1), 2021. PMID: 33980839.
4. Rocha, P, Salazar, R, Zhang, J, Ledesma, D, Solorzano, JL, Mino, B, Villalobos, P, Dejima, H, Douse, DY, Diao, L, Mitchell, KG, Le, X, Zhang, J, Weissferdt, A, Parra Cuentas, ER, Cascone, T, Rice, DC, Sepesi, B, Kalhor, N, Moran, C, Vaporciyan, AA, Heymach, JV, Gibbons, DL, Lee, JJ, Kadara, HN, Wistuba, II, Behrens, MC, Solis Soto, LM Correction to. Cancer Immunology, Immunotherapy 70(7):1977-1978, 2021. PMID: 33686493.

Abstracts

1. Khalil A, Fujimoto J, McDowell T, Scheet P, Nemer G, Kadara H. Early suppression of the TBX2 subfamily of transcription factors during in vivo tobacco carcinogen-mediated lung adenocarcinoma development. American Association for Cancer Research (AACR) Annual Meeting April 2018, Chicago, Illinois, USA, 2018. e-Pub 2018.
2. Khalil A, El-Hachem N, Dekmak B, Kadara H, Nemer G. Role of the evolutionarily conserved TBX2 subfamily of transcription factors in the molecular pathogenesis of human lung adenocarcinoma. American Association for Cancer Research (AACR) Annual Meeting April 2018, Chicago, Illinois, USA, 2018. e-Pub 2018.
3. Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Kalhor N, Moran C, El-Zein R, Davies G, Fujimoto J, Mehran R, Swisher S, Wang J, Fowler J, Dubinett S, Spira A, Ehli E, Wistuba I, Scheet P, Kadara H. Somatic mutational processes in the cancerization field of the normal-appearing airway reveal early drivers in the development of non-small cell lung cancer. American Association for Cancer Research (AACR) Annual Meeting April 2018, Chicago, Illinois, USA, 2018. e-Pub 2018.
4. Chen R, Fujimoto J, Reuben A, Ying L, Hu X, Chow CW, Canales J, Sun W, Hu J, Parra E, Behrens C, Wu CJ, Little L, Gumbs C, Wiesnoski D, Han G, Lee WC, Scheet P, Kadara H, Antonoff M, Vaporciyan AA, Wisher S, Zhang J, Heymach J, Hong WK, Wistuba II, Futreal A, Su D, Zhang J. T-cell repertoire evolution from the normal lung to invasive lung adenocarcinoma. American Association for Cancer Research (AACR) Annual Meeting April 2018, Chicago, Illinois, USA, 2018. e-Pub 2018.
5. Jakubek Y, San Lucas FA, Sivakumar S, Fowler J, Kadara H, Scheet P. Landscape of allelic imbalance in pan-cancer adjacent normal tissue: Insights into field cancerization and cancer pathogenesis. American Association for Cancer Research (AACR) Annual Meeting April 2018, Chicago, Illinois, USA, 2018. e-Pub 2018.
6. Sivakumar S, Jakubek Y, Lang W, McDowell T, Garcia MM, Chow C, Weber Z, Behrens C, Kalhor N, Moran C, El-Zein R, Davies G, Fujimoto J, Mehran R, Swisher SG, Wang J, Spira AE, Fowler J, Lucas F, Wistuba II, Ehli E, Scheet P, Kadara H. Mutational landscape in the normal-appearing airway cancerization field of early-stage non-small cell lung cancer. American Association for Cancer Research (AACR) Annual Meeting April 2017, Washington, D.C., USA, 2017. e-Pub 2017.
7. Tsao AS, Wistuba I, Xia D, Byers L, Diao L, Wang J, Papadimitrakopoulou V, Tang X, Lu W, Kadara H, Sauvage FD, Grigoryev D, Gumus ZH, Tan Z, Zhang S, Nilsson M, Heymach JV. Germline and somatic smoothened (SMO) mutations in non-small cell lung cancer (NSCLC) are potentially responsive to hedgehog inhibitor vismodegib. Annual ASCO meeting, June 2017. Chicago, Illinois, USA, 2017. e-Pub 2017.
8. Caetano MS, Van H, Bugarin E, Cumpian A, McDowell T, Zhang H, Evans SE, Watowich S, Kadara H, Moghaddam SJ. Gender specific function of epithelial IL-6-STAT3 pathway in KRAS mutant lung cancer. American Association for Cancer Research (AACR) Annual Meeting April 2017, Washington, D.C., USA, 2017. e-Pub 2017.
9. Jakubek YA, Sivakumar S, Strong LC, Kadara H, Scheet P. Intratumoral divergence of copy number alterations in NSCLC. American Association for Cancer Research (AACR) Annual Meeting April 2017, Washington, D.C., USA, 2017. e-Pub 2017.
10. Ochieng JK, Lang W, Nunomura-Nakamura S, McDowell T, Arlinghaus R, Imaoka Y, Hori T, Fukuoka J, Scheet P, Fujimoto J, Kadara H. Loss of Lcn2 promotes development of smoking-associated KRAS mutant lung cancer. American Association for Cancer Research (AACR) Annual Meeting April 2017, Washington, D.C., USA, 2017. e-Pub 2017.
11. Umer M, Cumpian AM, Khosravi N, Azzegagh Z, Mohebnasab M, Caetano MS, Ostrin EJ, Wistuba II, Dickey B, Kadara H, Evans CM, Moghaddam SJ. MUC5AC plays an essential role in promotion of KRAS mutant lung cancer. American Association for Cancer Research (AACR) Annual Meeting April 2017, Washington, D.C., USA, 2017. e-Pub 2017.
12. Fowler J, Lucas F, Sivakumar S, Deshpande A, Kadara H, Scheet P. Optimizing the replication of cancer genomics workflows: case studies. American Association for Cancer Research (AACR) Annual Meeting April 2017, Washington, D.C., USA, 2017. e-Pub 2017.
13. Seth S, Lee W, Zhang J, Fujimoto J, Behrens C, McDowell T, Kalhor N, Weissferdt A, Papadimitrakopoulou V, Heymach J, Gibbons D, Futreal P, Wistuba I, Moran C, Kadara H, Zhang J. Genomic and transcriptomic profiling of localized sarcomatoid carcinoma of the lung reveals association between immune activation and a lower risk of recurrence. Annual ASCO meeting, June 2017. Chicago, Illinois, USA, 2017. e-Pub 2017.
14. Skoulidis F, Elamin Y, Papadimitrakopoulou V, Tong P, Wang J, Lewis J, Rinsurongkawong W, Chu C, Roarty E, Zhang J, Tran H, Rodriguez-Canales J, Parra E, Behrens C, Kadara H, Wistuba II, Heymach J. Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy. IASLC annual meeting December 2016, Vienna, Austria, 2016. e-Pub 2016.
15. Ochieng J, Nunomura S, Lang W, Wei J, Xu L, McDowell C, Ostrin E, Arlinghaus R, Fujimoto J, Kadara H. Expression of the lipocalin 2 oncogene in the development of smoking-associated and Kras mutant lung adenocarcinoma. American Association for Cancer Research (AACR) Annual Meeting April 2016, New Orleans, LA, US, 2016. e-Pub 2016.
16. Parra E, Tong P, Kadara H, Papadimitrakopoulou V, Izzo J, Rodriguez-Canales J, Behrens C, Minna JD, Wang J, Wistuba II, Heymach JV, Skoulidis F. Impact of APOBEC mutagenesis on the immune microenvironment of lung adenocarcinoma (LUAC). American Association for Cancer Research (AACR) Annual Meeting April 2016, New Orleans, LA, USA, 2016. e-Pub 2016.
17. Fujimoto J, Nunomura S, Lang W, Liu Y, Wei J, Ochieng J, Jakubek Y, Ostrin E, Petersen J, Davies G, Darwiche N, Ehli E, Fowler J, Scheet P, Kadara H. Development of Kras mutant lung adenocarcinoma in tobacco carcinogen exposed mice with knockout of the airway lineage-specific G-protein coupled receptor Gprc5a. American Association for Cancer Research (AACR) Annual Meeting April 2016, New Orleans, LA, USA, 2016. e-Pub 2016.
18. Kadara H, Choi M, Zhang J, Parra E, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach JV, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton R, Herbst RS, Wistuba II. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma. American Association for Cancer Research (AACR) Annual Meeting April 2016, New Orleans, LA, USA, 2016. e-Pub 2016.
19. Choi M, Kadara H, Zhang J, Parra E, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach JV, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton R, Herbst RS, Wistuba II. Mutation and immune profiles in early-stage lung squamous cell carcinoma. American Association for Cancer Research (AACR) Annual Meeting April 2016, New Orleans, LA, USA, 2016. e-Pub 2016.
20. Scheet P, Jakubek Y, Lang W, Vattahil S, Garcia M, Huang L, Lu W, chow C, Weber Z, Davies GE, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran RJ, Fowler J, Ehli EA, Wistuba II, Kadara H. The genomic landscape of allelic imbalance in the normal-appearing airway field of cancerization. 2015 Innovations in Cancer Prevention and Research Institute of Texas Conference, 2015. e-Pub 2015.
21. Skoulidis F, Denning W, Diao L, Tong P, Fan YH, Papadimitrakopoulou V, Izzo J, Behrens C, Kadara H, Parra Cuentas ER, Rodriguez J, Wang J, Gibbons DL, Byers LA, Wistuba II, Heymach J. Association of inactivation of STK11/LKB1 with a suppressive immune microenvironment in lung adenocarcinoma (LUAC). American Society for Clinical Oncology (ASCO) Annual Meeting June 2015, Chicago, IL, USA, 2015. e-Pub 2015.
22. Skoulidis F, Denning W, Diao L, Tong P, Fan YH, Papadimitrakopoulou V, Izzo J, Behrens C, Kadara H, Parra Cuentas ER, Rodriguez-Canales J, Wang J, Byers LA, Wistuba II, Heymach J. Impact of co-mutations on the immune microenvironment of KRAS-mutant lung adenocarcinoma. IASLC annual meeting 2015, 2015. e-Pub 2015.
23. Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Lou Y, Gibbons DL, Heymach JV, Swisher SG, Weissferdt A, Kahlor N, Izzo J, Lee J, Kadara H, Moran C, Wistuba II. High programmed cell death ligand 1 expression and low immune infiltrate score correlate with worse outcome in patients with lung adenocarcinoma. American Association for Cancer Research (AACR) Annual Meeting April 2015, Philadelphia, PA, USA, 2015. e-Pub 2015.
24. Jakubek Y, Lang W, Vattahil S, Garcia M, Huang L, Lu W, chow C, Weber Z, Davies GE, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran RJ, Fowler J, Ehli EA, Wistuba II, Scheet P, Kadara H. The landscape of allelic imbalance in the normal-appearing airway field of cancerization. American Association for Cancer Research (AACR) Annual Meeting April 2015, Philadelphia, PA, USA, 2015. e-Pub 2015.
25. Skoulidis F, Byers L, Diao L, Papadimitrakopolou V, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan YH, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong K, Zhang J, Sharma P, Mills GM, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occuring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities. American Association for Cancer Research (AACR) Annual Meeting April 2015, Philadelphia, PA, USA, 2015. e-Pub 2015.
26. Caetano MS, Cumpian AM, Gong L, Chang SH, Zhang H, Kadara H, Sternberg C, Ferreira CG, Watowich SS, Moghaddam SJ. Targeting IL-6 as a preventive and therapeutic strategy for K-ras mutant lung cancer. American Association for Cancer Research (AACR) Annual Meeting April 2015, Philadelphia, PA, USA, 2015. e-Pub 2015.
27. Kusko R, Garrison C, Wang T, Campbell J, Perez-Rogers J, Luo L, Beane J, Liu G, Kadara H, Belinsky S, Lendburg M, Spira A. Gene and miRNA expression networks specific to never smoker lung adenocarcinoma. American Association for Cancer Research (AACR) Annual Meeting April 2014, San Diego, CA, USA, 2014. e-Pub 2014.
28. Maki Y, Fujimoto J, Yoo SY, Garcia MM, Gower A, Shen L, Chow CW, Behrens C, Kalhor N, Moran C, Wang J, Spira A, Coombes KR, Wistuba I, Kadara H. Transcriptomic architecture of the field of cancerization in the adjacent normal-appearing airway: Early mechanisms in lung carcinogenesis. American Association for Cancer Research (AACR) Annual Meeting April 2014, San Diego, CA, USA, 2014. e-Pub 2014.
29. Fujimoto J, Zhang J, Pickering C, Kadara H, Muzny D, Weissfedrt A, Wheeler DA, Myers J, Wang J, Wistuba I, Kalhor N, Moran C. Identification of novel somatic variants in thymic epithelial tumors by next-generation sequencing. United States & Canadian Academy of Pathology (USCAP) Annual Meeting MArch 2014, San Diego, CA, USA, 2014. e-Pub 2014.
30. Kusko R, Anderlind C, Wang G, Zhang S, Wallace W, Wasler T, Ebright M, Garcia MM, Eisenberg R, Lee G, Liu G, Elashoff D, Kalhor N, Moran C, Mehran R, Fujimoto J, Massion PP, Dubinett S, Wistuba I, Lendburg M, Kadara H, Spira A. Mapping the airway-wide molecular field of injury in smokers with lung cancer. American Association for Cancer Research (AACR) Annual Meeting April 2014, San Diego, CA, USA, 2014. e-Pub 2014.
31. Sen B, Peng S, Mazumdar T, Byers LA, Kadara H, Johnson FM. The multitargeted kinase inhibitor dasatinib induces DNA damage, Hippo pathway engagement and senescence in lung cancer cell lines that possess kinase-inactivating BRAF mutations. American Association for Cancer Research (AACR) Annual Meeting April 2014, San Diego, CA, USA, 2014. e-Pub 2014.
32. Fujimoto J, Kadara H, Wistuba I. Challenges to investigate lung carcinogenesis at the University of Texas MD Anderson Cancer Center Thoracic Molecular Pathology Laboratory. 18th Congress of the Asian Pacific Society of Respirology, 2013. e-Pub 2013.
33. Maki Y, Fujimoto J, Yoo S, Gower A, Shen L, Garcia MM, Kabbout M, Chow C, Hong WK, Kalhor N, Wang J, Moran C, Spira A, Coombes KR, Wistuba II, Kadara H. Transcriptomic architecture of the airway field cancerization in early-stage non-small cell lung cancer. American Association for Cancer Research (AACR) Annual Meeting April 2013, Washington, D.C., USA, 2013. e-Pub 2013.
34. Kadara H, Fujimoto J, Yoo S, Garcia M, Kabbout M, Basey A, Wang J, Coombes KR, Kim ES, Hong WK, Kalhor N, Moran C, Wistuba II. Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential targets for chemoprevention in early stage lung cancer patients. American Association for Cancer Research (AACR) Annual Meeting April 2012, Chicago, Illinois, USA, 2012. e-Pub 2012.
35. Fujimoto J, Kadara H, Woo SK, Melinda Garcia M, Kabbout M, Basey A, Wang J, Coombes KR, Kim ES, Hong WK, Kalhor N, Moran C, Wistuba II. Gene expression profiling of lung field cancerization reveals potential targets for chemoprevention. Annual Meeting of the Japanese Society of Pathology April 2012, Japan, 2012. e-Pub 2012.
36. Fujimoto J, Suraokar M, Fukuoka J, Aoe K, Kadara H, Behrens C, Hori T, Fujimoto N, Kishimoto T, Inai K, Hiroshima K, Mehran R, Tsao A, Wistuba II. The University of Texas MD Anderson Cancer Center Mesothelioma Program. The 53rd Annual Meeting of the Japan Lung Cancer Society, 2012. e-Pub 2012.
37. Kabbout M, Garcia M, Fujimoto J, Chow C, Woods D, Koch P, Momin A, James BP, MSolis L, Behrens C, Wistuba I, Kadara H. Tumor suppressor effects of ETS2 transcriptional factor in human non-small cell lung cancer pathogenesis. American Association for Cancer Research (AACR) Annual Meeting April 2012, Chicago, Illinois, USA, 2012. e-Pub 2012.
38. Fujimoto J, Kadara H, Fukuoka J, Aoe K, Fujimoto N, Kushimoto T, Inai K, Hiroshima K, Suraokar M, Tsao A, Mehran R, Wistuba II. Expression patterns of the G-protein coupled-receptor, GPRC5A, in human malignant pleural mesothelioma. American Association for Cancer Research (AACR) Annual Meeting April 2012, Chicago, Illinois, USA, 2012. e-Pub 2012.
39. Riquelme E, Behrens C, Suraokar M, Chow C, Kadara H, Wistuba II, Girard L, Minna JD. EZH2High and miR-101Low expressions are associated with chemoresistance and shorter survival in patients with lung adenocarcinoma who received adjuvant therapy. American Association for Cancer Research (AACR) Annual Meeting April 2012, Chicago, Illinois, USA, 2012. e-Pub 2012.
40. Behrens C, Solis L, Lin H, Tang X, Yuan P, Kadara H, Riquelme E, Galindo H, Hong WK, Lee J, Wistuba II. Analysis of EZH2 and TITF-1 protein expression identifies a subset of lung adenocarcinomas with better prognosis. American Association for Cancer Research (AACR) Annual Meeting April 2012, Chicago, Illinois, USA, 2012. e-Pub 2012.
41. Kadara H, Saintigny P, Fan Y, Chow C, Chu Z, Lang W, Behrens C, Gold K, Liu D, Lee J, Mao L, Kim ES, Hong WK, Wistuba II. Gene expression analysis of field of cancerization in early stage NSCLC patients towards development of biomarkers for personalized prevention. American Association for Cancer Research (AACR) Annual Meeting April 2011, Orlando, FL, USA, 2011. e-Pub 2011.
42. Fujimoto J, Kadara H, Behrens C, Liu D, Lee J, Fukuoka J, Solis LM, Kim ES, Shalafkhane A, Wistuba II, Lotan R. The G-protein coupled receptor family C group 5 member A loss is implicated in lung carcinogenesis. Japanese Society of Pathology Annual Meeting April 2011, Japan, 2011. e-Pub 2011.
43. Kadara H, Saintigny P, Shen L, Chow C, Chu Z, Lang W, Kabbout M, Fan Y, Behrens C, Gold K, Liu D, Lee J, Mao L, Wang J, Coombes KR, Kim E, Hong WK, Wistuba II. Field of cancerization molecular profiling in early stage NSCLC patients towards development of biomarkers for personalized prevention. World Conference on Lung Cancer (WCLC) July 2011, Amsterdam, Netherlands, 2011. e-Pub 2011.
44. Behrens C, Yuan P, Solis L, Saintigny P, Kadara H, Fujimoto J, Moran C, Swisher SG, Heymach JV, Wistuba II. EZH2 expression is an early event in the pathogenesis of non-small cell lung cancer (NSCLC) and correlates with tumor progression. American Association for Cancer Research (AACR) Annual Meeting April 2012, Orlando, FL, USA, 2011. e-Pub 2011.
45. Fujimoto J, Kadara H, Behrens C, Liu D, Lee J, Solis LM, Kim E, Sharafkhaneh A, Wistuba II, Reuben L. Implication of GPRC5A loss in lung carcinogenesis in patients with and without chronic obstructive pulmonary disease. American Association for Cancer Research (AACR) Annual Meeting April 2011, Orlando, FL, USA, 2011. e-Pub 2011.
46. Wistuba II, Kadara H, Kim ES, Hong WK. Molecular Pathology of Lung Cancer & Intermediate Markers of Carcinogenesis. World Conference on Lung Cancer (WCLC) July 2011, Amsterdam, Netherlands, 2011. e-Pub 2011.
47. Cascone T, Herynk MH, Xu L, Kadara H, Hanrahan E, Fan Y, Siagal B, Park Y, Lee J, Langley RR, Jurgensmeier JM, Ryan A, Heymach JV. Increased HGF is associated with resistance to VEGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). American Association for Cancer Research (AACR) Annual Meeting April 2010, Washington, D.C., USA, 2010. e-Pub 2010.
48. Kadara H, Hong WK, Wistuba II, Lotan R. A five-gene signature predictive of survival in lung adenocarcinoma but not in squamous cell carcinoma. American Association for Cancer Research (AACR) Annual Meeting April 2010, Washington, D.C., USA, 2010. e-Pub 2010.
49. Chen Y, Deng J, Fujimoto J, Kadara H, Ye X, Men T, Lotan D, Lotan R. Loss of the lung-specific tumor suppressor Gprc5a causes persistent activation of Stat3 leading to increased survival signaling in normal and malignant lung epithelial cells. American Association for Cancer Research (AACR) Annual Meeting April 2010, Washington, D.C., USA, 2010. e-Pub 2010.
50. Fujimoto J, Kadara H, Tao Q, Men T, Pelt CV, Lotan D, Lotan R. Tobacco carcinogen-enhanced lung tumorigenesis in Gprc5a knockout mice recapitulates human lung cancer development. American Association for Cancer Research (AACR) Annual Meeting April 2010, Washington, D.C., USA, 2010. e-Pub 2010.
51. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. American Association for Cancer Research (AACR) Annual Meeting April 2010, Washington, D.C., USA, 2010. e-Pub 2010.
52. Kadara H, Behrens C, Solis L, Minna JD, Hong W, Wistuba II, Lotan R. A five-gene signature predictive of survival in early stage lung adenocarcinoma but not in squamous cell carcinoma. Joint IASLC-AACR conference on the molecular origins of lung cancer January 2010, San Coronado, CA, USA, 2010. e-Pub 2010.
53. Kadara H, Fujimoto J, Men T, Ye X, Lotan D, Lee J, Lotan R. A murine loss of lung tumor suppressor gene signature predicts poor survival in human NSCLC. IASLC 9th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting February 2009, Santa Monica, CA, USA, 2009. e-Pub 2009.
54. Cascone T, Herynk M, Du D, Kadara H, Hanrahan EO, Nilsson MB, Lin HY Lee JJ, Park YY, Lee JS, Heymach JV. Stromal HGF and VEGFR-1 are associated with acquired resistance to VEGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC). World Conference on Lung Cancer (WCLC) August 2009, San Francisco, CA, USA, 2009. e-Pub 2009.
55. Kadara H, Fujimoto J, Men T, Lotan D, Ye X, Lee J, Lotan R. Gene expression signatures of tumor suppressor Gprc5a loss in murine lung cells predict poor survival in human lung adenocarcinomas. American Association for Cancer Research (AACR) Annual Meeting April 2009, Denver, CO, USA, 2009. e-Pub 2009.
56. Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee J, Tahara E, Hong WK, Wistuba II, Lotan R. Identification of prognostic markers by integrative gene expression analysis of an in vitro model of lung carcinogenesis and their validation in lung cancer tissue specimens. American Association for Cancer Research (AACR) Annual Meeting April 2009, Denver, CO, USA, 2009. e-Pub 2009.
57. Cascone T, Herynk MH, Du D, Oborn CJ, Kadara H, Nilsson M, Lee J, Langley RR, Heymach JV. A role for stromal EGFR activation in resistance to VEGF blockade in human non-small cell lung cancer (NSCLC) xenograft models. American Association for Cancer Research (AACR) Annual Meeting April 2009, Denver, CO, USA, 2009. e-Pub 2009.
58. Kadara H, Lee J, Ye X, Men T, Lotan D, Lotan AR. Murine loss of tumor suppressor Gprc5a gene expression signatures are associated with poor prognosis in human lung adenocarcinomas. University of Texas MD Anderson Cancer Center 61st Annual symposium in Cancer Research Systems Biology of Cancer November 2008, Houston, TX, USA, 2008. e-Pub 2008.
59. Kadara H, Kim H, Tahara E, Lotan D, Lotan AR. Differential effects of 4HPR on gene expression and apoptosis in normal and malignant cells of the head and neck despite induction of reactive oxygen species in both cell types. American Association for Cancer Research (AACR) Annual Meeting April 2008, San Diego, CA, USA, 2008. e-Pub 2008.
60. Tahara E, Kadara H, Lacroix L, Lotan D, Lotan R. Inhibition of lung cancer cell growth by the putative tumor suppressor gene KLF6 through activation of Protein kinase C alpha and inhibition of the PI3kinase pathway. American Association for Cancer Research (AACR) Annual Meeting April 2008, Los Angeles, CA, USA, 2007. e-Pub 2007.
61. Lacroix L, Tahara E, Behrens C, Kadara H, Lotan D, Wistuba II, Lotan R. Identification of biomarkers for human lung carcinogenesis by analysis of transcriptomes of cell lines representing different stages of lung carcinogenesis. American Association for Cancer Research (AACR) Annual Meeting April 2008, Los Angeles, CA, USA, 2007. e-Pub 2007.
62. Chakravarti N, Kadara H, Lacroix L, Yoon D, Shay JW, Myers J, Lotan D, Lotan R. Inhibition of cell Growth in head and neck premalignant cells by curcumin in an eIF4E-dependent manner. American Association for Cancer Research (AACR) Annual Meeting April 2008, Los Angeles, CA, USA, 2007. e-Pub 2007.
63. Kadara H, Tahara E, Kim H, Lotan D, Myers J, Lotan R. Differential Rac-mediated generation of reactive oxygen species increases sensitivity of metastatic cancer cells to the proapoptotic synthetic retinoid 4HPR relative to their primary cancer cell counterparts. American Association for Cancer Research (AACR) Annual Meeting April 2008, Los Angeles, CA, USA, 2007. e-Pub 2007.
64. Kadara H, Myers J, Lotan R. Implication of Rac-mediated Generation of Reactive Oxygen Species in Enhanced Sensitivity of Metastatic Head and Neck Cancer Cells to Induction of Apoptosis by the Synthetic Retinoid 4HPR Relative to their Corresponding Primary Cancer Cells. 15th SPORE Investigators’ Workshop July 2007, Baltimore, MD, USA, 2007. e-Pub 2007.
65. Kadara H, Lacroix L, Lotan D, Lotan R. The pro-apoptotic retinoid N-(4-hydroxyphenyl)retinamide activates the endoplasmic reticulum stress pathway in 22B human head and neck cancer cells. American Association for Cancer Research (AACR) Annual Meeting April 2006, Washington, D.C., USA, 2006. e-Pub 2006.
66. Lotan R, Kim H, Chakravarti N, Lacroix L, Lotan D, Kadara AH. Pivotal role of reactive oxygen species and MAP kinases in induction of cell death pathways by the synthetic retinoid fenretinide. 14th SPORE Investigators’ Workshop July 2006, Baltimore, MD, USA, 2006. e-Pub 2006.
67. Schroeder C, Kadara H, Lotan AR. Combination of Celecoxib and 4HPR exhibits enhanced apoptosis by increasing mitochondrial membrane permeability and suppressing PI3K/AKT-signaling pathway in BEAS-2B immortalized human bronchial epithelial cells. American Association for Cancer Research (AACR) Annual Meeting April 2005, Anaheim, CA, USA, 2005. e-Pub 2005.

Book Chapters

1. Sinjab, A, Daouk, R, Abou-Kheir, W, Kadara, HN. Whole Transcriptome Sequencing Analysis of Cancer Stem/Progenitor Cells Obtained from Mouse Lung Adenocarcinomas, 187-198, 2021.
2. Kadara H, Franklin W, Wistuba II. Inflammation and lung cancer: molecular pathology. In: Inflammation & Lung Cancer. Springer, 2015.
3. Kadara H, Wistuba II. Molecular biology of lung preneoplasia. In: Lung Cancer. Fourth edition. Springer US-Cancer Research, 2013.
4. Kadara H, Lotan R. Effects of natural and synthetic retinoids on the differentiation and growth of squamous cancers. In: Signaling Pathways in Squamous Cancers. Springer US-Cancer Research, 2010.